These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26600787)

  • 1. Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases.
    Cherin P; Delain JC; de Jaeger C; Crave JC
    Case Rep Neurol; 2015; 7(3):227-32. PubMed ID: 26600787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.
    Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E
    Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases.
    Cherin P; Tadmouri A; de Jaeger C; Pindi Sala T; Crave JC
    Ther Adv Musculoskelet Dis; 2018 Oct; 10(10):201-207. PubMed ID: 30327686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.
    Danieli MG; Verga JU; Mezzanotte C; Terrenato I; Svegliati S; Bilo MB; Moroncini G
    Front Immunol; 2021; 12():805705. PubMed ID: 35111165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin for patients with idiopathic inflammatory myopathies: a real-world, single-centre experience.
    Ma Z; Johnson D; Gniadecki R; Ritchie B; Keeling S; Cohen Tervaert JW; Osman M
    Rheumatology (Oxford); 2024 Aug; 63(8):2118-2122. PubMed ID: 37796840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous immunoglobulin therapy in statin-induced necrotizing autoimmune myopathy.
    Mak VP; Gravely K; Lim SY
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):58-61. PubMed ID: 32967573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent anti-PM-Scl antibody-associated systemic sclerosis and inclusion body myositis - report of two cases and review of the literature.
    Chatterjee S; Prayson RA
    Semin Arthritis Rheum; 2020 Jun; 50(3):498-502. PubMed ID: 31806155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.
    Walter MC; Lochmüller H; Toepfer M; Schlotter B; Reilich P; Schröder M; Müller-Felber W; Pongratz D
    J Neurol; 2000 Jan; 247(1):22-8. PubMed ID: 10701893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
    Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
    Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin.
    Soueidan SA; Dalakas MC
    Neurology; 1993 May; 43(5):876-9. PubMed ID: 8492940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inclusion body myositis (IBM) -- a review].
    Czaplinski A; Renaud S; Fuhr P
    Praxis (Bern 1994); 2003 Apr; 92(14):649-54. PubMed ID: 12723314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous immunoglobulin therapy on anti-NT5C1A antibody-positive inclusion body myositis after successful treatment of hepatitis C: A case report.
    Takamiya M; Takahashi Y; Morimoto M; Morimoto N; Yamashita S; Abe K
    eNeurologicalSci; 2019 Sep; 16():100204. PubMed ID: 31517073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review.
    Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F
    Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy.
    Eftimov F; Vermeulen M; de Haan RJ; van den Berg LH; van Schaik IN
    J Peripher Nerv Syst; 2009 Jun; 14(2):93-100. PubMed ID: 19691531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases.
    Chen Y; Wang C; Xu F; Ming F; Zhang H
    Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
    Dalakas MC
    Neurology; 1998 Dec; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
    Illa I
    J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose subcutaneous immunoglobulins for the treatment of severe treatment-resistant polymyositis.
    Patrick C; Jean-Christophe D; Jean-Charles C; Odile C
    Case Rep Rheumatol; 2014; 2014():458231. PubMed ID: 25140268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.